share_log

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

HAVN Life完成ABO 7月第一批融資,修訂細節和債務股份發行
Benzinga Real-time News ·  2022/08/19 16:06
Biotech psychedelics company HAVN Life Sciences Inc. (OTC:HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean ("ABO"), previously announced on July 21, 2022. 
生物技術迷幻藥公司HAVN生命科學公司(場外交易代碼:HAVLF)最近完成了與創新基金的首批融資協議阿爾法藍海(《ABO》),此前於2022年7月21日宣佈。
Since its creation in 2017, ABO has executed more than $1.5 billion in financial commitments and more than 90 ‎transactions, mostly within the life sciences sector, all around the globe.
自2017年成立以來,ABO已經執行了超過15億美元的財務承諾以及90多筆‎交易,其中大部分是全球生命科學領域的交易。
Following the current first-tranche closing, HAVN issued to the investment fund managed by ABO "Global Corporate Finance Opportunities 17" a total $1,100,000 principal amount of senior unsecured convertible debenture as well as 189,393 common share purchase warrants for net proceeds of approximately $420,000.
在目前的第一批結束後,HAVN向ABO管理的投資基金《全球企業融資機會17》總計1,100,000美元的優先無擔保可轉換債券本金以及189,393份普通股認購權證,淨收益約為420,000美元。
The convertible debenture may...
這個可轉...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論